The scale is the dumbest instrument in your cutting toolkit. It tells you that mass left your body. It does not tell you whether that mass was visceral fat, subcutaneous fat, glycogen, intracellular water, or — if your protocol is wrong — appendicular muscle. During a cut, a one-pound-per-week drop on the bathroom scale can mean you reversed metabolic syndrome or that you accelerated sarcopenia. The labs sort that out. Everything else is guessing.
The other reason labs matter on a cut: your body actively distorts the markers your physician was trained to read. Caloric deficit upregulates reverse T3 to block thyroid signaling at the cellular level. Cortisol climbs. Leptin collapses. If you stack GH secretagogues on top, fasting insulin can paradoxically rise because growth hormone antagonizes insulin at the receptor. A standard primary-care lab panel — TSH, total cholesterol, fasting glucose — will tell you almost nothing useful. The corpus is consistent: most metabolic dysfunction goes unmeasured because the wrong markers are pulled at the wrong times.
Why standard labs lie during a cut
Three biological realities make the cutting phase the worst time to rely on conventional markers.
First, thyroid adaptation. When nutrients are scarce, the body increases production of reverse T3 to block the effects of T3 — this is a feature, not a bug. It exists to slow metabolism when fuel is limited. The pattern you will see is not low free T3 alone; it's low free T3 paired with elevated reverse T3, meaning the conversion enzymes have shifted away from active hormone. TSH stays normal. T4 stays normal. The cellular thyroid signal is suppressed. Conventional thyroid panels miss this entirely because reverse T3 is rarely ordered.
Second, the insulin–GH paradox. Practitioner consensus is unambiguous here: GH secretagogues (Ipamorelin, CJC-1295, Tesamorelin) can worsen insulin resistance because growth hormone naturally antagonizes insulin. If your baseline fasting insulin is elevated entering the cut, layering a GH stack pushes you further into metabolic dysfunction — even while you're losing weight on the scale. The cut is hiding the insulin lesion. You won't see it until you stop dieting and refeed.
Third, what visceral fat tells you that BMI cannot. Visceral fat is a relatively small fraction of total body fat, but it's far more predictive of metabolic risk than the total mass loss number. A cut that drops 10 pounds of subcutaneous fat from your legs but leaves visceral adipose tissue untouched is a cosmetic win and a metabolic non-event. DEXA separates these. The scale cannot.
The lab schedule
Pull these markers at the cadence below. Baseline before injection one is non-negotiable — without it, every follow-up number is meaningless noise.
| Marker | Tier | When to Pull | What It Tells You |
|---|---|---|---|
| DEXA scan (body composition + VAT) | 🔵 Clinical | Baseline + Week 10 | Bone, fat (subcutaneous vs visceral), appendicular lean mass. The only honest readout of what you lost. |
| Fasting insulin | 🔵 Clinical | Baseline + Week 6 + Week 10 | Standard ranges go up to 24 — that's metabolic disaster zone. Target single digits. Elevated baseline contraindicates GH secretagogues until corrected. |
| HOMA-IR (calculated: fasting insulin × fasting glucose / 405) | 🔵 Clinical | Baseline + Week 10 | Insulin resistance quantified. The substrate calls this the cheapest, most predictive metabolic marker available. |
| HbA1c | 🔵 Clinical | Baseline + Week 10 | Three-month glucose average. Tesamorelin trials showed 0.32% reduction alongside 3.86% weight loss — a meaningful metabolic signal. |
| Free T3 + Reverse T3 (both — never one without the other) | 🟢 Expert | Baseline + Week 4 + Week 8 | The fT3:rT3 ratio is your adaptive-thermogenesis readout. Falling fT3 with rising rT3 = the body is downshifting metabolism. |
| TSH + Free T4 | 🔵 Clinical | Baseline + Week 10 | Confirms central thyroid output is intact. If TSH stays normal but fT3 collapses, the lesion is peripheral conversion. |
| Lipid panel (full — including triglycerides and HDL separately) | 🔵 Clinical | Baseline + Week 10 | Trig:HDL ratio is the real cardiovascular signal, not total cholesterol. Target 1:1. Above 2 means insulin resistance. |
| ApoB | 🔵 Clinical | Baseline + Week 10 | Particle count. The substrate is explicit: a low LDL with high ApoB still carries risk. |
| IGF-1 | 🟢 Expert | Baseline + Week 6 (if running Tesamorelin/Ipamorelin/CJC) | The response marker for any GH secretagogue. Low baseline correlates with metabolic dysfunction; rising IGF-1 on protocol confirms the axis is firing. |
| Leptin | 🟢 Expert | Baseline + Week 10 | Falls during deficit. A floor-collapse signals the body is entering aggressive defense mode — appetite, cravings, and metabolic rate all respond. |
| CBC + Liver panel (AST/ALT) | 🔵 Clinical | Baseline + Week 6 | Multi-compound load monitoring. The mega-regen substrate flags Week 6 as the inflection point for liver elevations on stacked protocols. |
| hs-CRP | 🔵 Clinical | Baseline + Week 10 | Systemic inflammation. Should fall on a clean cut; rising hs-CRP means the deficit is pathological, not adaptive. |
| Amylase + Lipase | 🔵 Clinical | If running GLP-1 (Semaglutide/Tirzepatide) — Week 4 + Week 8 | Greater than 3× upper limit = pancreatitis risk; stop. Non-negotiable. |
| hsCRP, fasting glucose, fasting insulin in same draw | 🔵 Clinical | Weeks 4 + 8 (cheap interim check) | The interim "is the protocol working without harming me" panel. |
What you should see week by week
- Week 2: Nothing on labs yet — pulling now wastes a draw. The body needs ~4 weeks for thyroid and IGF-1 to register a meaningful signal.
- Week 4: First fT3/rT3 check. Expect modest fT3 dip; rT3 should not yet be climbing aggressively if the deficit is well-managed. IGF-1 (if running GH secretagogues) should be measurably elevated from baseline.
- Week 6: Mid-protocol checkpoint. Liver panel and fasting insulin. AST/ALT elevations here flag compound load; insulin should be trending down if metabolic improvement is happening.
- Week 8: Second thyroid pull. If fT3 is collapsing and rT3 is climbing sharply, the deficit is too aggressive — the body is defending. Adjust calories up before adjusting compounds.
- Week 10: Full repeat — DEXA, HOMA-IR, HbA1c, lipid panel, ApoB, leptin, IGF-1. This is your verdict.
What's NOT happening yet
- The scale is not the readout. A 10-pound drop with worsening visceral fat is a failed cut. The DEXA tells you what you actually lost.
- TSH alone is not a thyroid check. Conventional doctors don't check reverse T3. You will. TSH staying in range while fT3 falls and rT3 rises is the most common missed lesion in cutting protocols.
- LDL is not the lipid story. When you stratify, HDL and triglycerides are the clear risk indicators; LDL becomes nearly irrelevant when both are favorable. Stop chasing total cholesterol.
- Caliper readings are not body composition. The substrate is blunt: calipers are highly dependent on the skill of the individual doing the test. Get a DEXA or get nothing.
- A "normal" fasting insulin reference range is not a clean readout. Standard ranges go up to 24. That is not a target — that is metabolic disaster being called normal.
- One DEXA is not a trend. It's a baseline. The second one — Week 10 — is the data point that matters.
Research describes this. Track it. Adjust.